Companion diagnostics (CDx) are diagnostic tests specifically designed to identify patients likely to benefit from a particular treatment. They provide essential information to guide treatment decisions.
The global companion diagnostics market is on the rise. In 2023, it was estimated at $7.6 billion, and it is projected to reach $15.4 billion by 2028, growing at a compound annual growth rate (CAGR) of 15.2%.